Watts RA, Hatemi G, Burns JC, Mohammad AJ (2022) Global epidemiology of vasculitis. Nat Rev Rheumatol 18:22–34. https://doi.org/10.1038/s41584-021-00718-8

Article  PubMed  Google Scholar 

Jin Y, He X, Lin W, Peng Z, Li W, Xiang W, Chen Z, Fu H, Mao J (2014) Serum cytokine profiles in children with IgA vasculitis with nephritis. Biomol Biomed. https://doi.org/10.17305/bb.2024.11081

Sugino H, Sawada Y, Nakamura M (2021) IgA vasculitis: etiology, treatment, biomarkers and epigenetic changes. Int J Mol Sci 22:7538. https://doi.org/10.3390/ijms22147538

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 360:666–670. https://doi.org/10.1016/S0140-6736(02)09835-5

Article  PubMed  Google Scholar 

Coppo R, Andrulli S, Amore A, Gianoglio B et al (2006) Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis 47:993–1003. https://doi.org/10.1053/j.ajkd.2006.02.178

Article  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1-1S276. https://doi.org/10.1016/j.kint.2021.05.021

Article  Google Scholar 

Ozen S, Marks SD, Brogan P, Groot N et al (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58:1607–1616. https://doi.org/10.1093/rheumatology/kez041

Article  CAS  PubMed  Google Scholar 

Vivarelli M, Samuel S, Coppo R, Barratt J et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533–569. https://doi.org/10.1007/s00467-024-06502-6

Article  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117-117S314. https://doi.org/10.1016/j.kint.2023.10.018

Article  Google Scholar 

Pillebout E, Alberti C, Guillevin L, Ouslimani A et al (2010) Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 78:495–502. https://doi.org/10.1038/ki.2010.150

Article  CAS  PubMed  Google Scholar 

Koskela M, Jahnukainen T, Endén K, Arikoski P et al (2019) Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study. Pediatr Nephrol 34:1447–1456. https://doi.org/10.1007/s00467-019-04238-2

Article  PubMed  Google Scholar 

Gan Y, Chen J, Wang M, Li Q et al (2024) The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases. Clin Kidney J 17:sfae15. https://doi.org/10.1093/ckj/sfae115

Article  CAS  Google Scholar 

Hackl A, Becker JU, Körner LM, Ehren R et al (2018) Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 33:619–629. https://doi.org/10.1007/s00467-017-3846-6

Article  PubMed  Google Scholar 

Singh S, Devidayal KL, Joshi K et al (2002) Severe Henoch-Schönlein nephritis: resolution with azathioprine and steroids. Rheumatol Int 22:133–137. https://doi.org/10.1007/s00296-002-0208-9

Article  CAS  PubMed  Google Scholar 

Zhang X, Xie X, Shi S, Liu L et al (2020) Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. Nephrol Dial Transplant 35:2117–2123. https://doi.org/10.1093/ndt/gfz151

Article  CAS  PubMed  Google Scholar 

O’Donoghue DJ, Jewkes F, Postlethwaite RJ, Ballardie FW (1992) Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. Clin Sci (Lond) 83:281–287. https://doi.org/10.1042/cs0830281

Article  CAS  PubMed  Google Scholar 

Oleinika K, Mauri C, Salama AD (2019) Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol 15:11–26. https://doi.org/10.1038/s41581-018-0074-7

Article  CAS  PubMed  Google Scholar 

Prieto-Peña D, Genre F, Remuzgo-Martínez S, Pulito-Cueto V et al (2021) BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep 11:11510. https://doi.org/10.1038/s41598-021-91055-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fenoglio R, Sciascia S, Naretto C, De Simone E et al (2020) Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. Clin Exp Rheumatol 38(Suppl 124):195–200

PubMed  Google Scholar 

Crayne CB, Eloseily E, Mannion ML, Azerf SP et al (2018) Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J 16:71. https://doi.org/10.1186/s12969-018-0285-2

Article  PubMed  PubMed Central  Google Scholar 

Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB et al (2009) Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura. J Pediatr 155:136–139. https://doi.org/10.1016/j.jpeds.2008.12.049

Article  CAS  PubMed  Google Scholar 

Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264. https://doi.org/10.1146/annurev.immunol.21.120601.141152

Article  CAS  PubMed  Google Scholar 

Wu D, Li J, Xu D, Merrill JT et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83:475–487. https://doi.org/10.1136/ard-2023-224854

Article  CAS  PubMed  Google Scholar 

Gao H, Lin J, Yang M, Gui M et al (2024) Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keae601

Article  PubMed  Google Scholar 

Liu L, Liu Y, Li J, Tang C et al (2024) Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study. Nephron 149:1–10. https://doi.org/10.1159/000540326

Article  CAS  PubMed  Google Scholar 

Lv J, Liu L, Hao C, Li G et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499–506. https://doi.org/10.1016/j.ekir.2022.12.014

Article  PubMed  Google Scholar 

Zhang L, Jin H, Wang D, Wang Y (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept. Front Immunol 14:1268929. https://doi.org/10.3389/fimmu.2023.1268929

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhillon S (2021) Telitacicept: first approval. Drugs 81:1671–1675. https://doi.org/10.1007/s40265-021-01591-1

Article  CAS  PubMed  Google Scholar 

Shi F, Xue R, Zhou X, Shen P et al (2021) Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43:666–673. https://doi.org/10.1080/08923973.2021.1973493

Article  CAS  PubMed  Google Scholar 

Wang M, Ma J, Yao L, Fan Y (2024) Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J 17:sfae85. https://doi.org/10.1093/ckj/sfae285

Article  Google Scholar 

Davin JC, Coppo R (2014) Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol 10:563–573. https://doi.org/10.1038/nrneph.2014.126

Article  CAS